TY - JOUR T1 - A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. AU - Quinn,Joseph F, AU - Harris,Christopher J, AU - Cobb,Katherine E, AU - Domes,Christopher, AU - Ralle,Martina, AU - Brewer,George, AU - Wadsworth,Teri L, PY - 2010/8/10/entrez PY - 2010/8/10/pubmed PY - 2011/1/19/medline SP - 903 EP - 14 JF - Journal of Alzheimer's disease : JAD JO - J Alzheimers Dis VL - 21 IS - 3 N2 - There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-β are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-β pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-β levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/20693639/A_copper_lowering_strategy_attenuates_amyloid_pathology_in_a_transgenic_mouse_model_of_Alzheimer's_disease_ L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-2010-100408 DB - PRIME DP - Unbound Medicine ER -